Novel 7-methoxy-6-oxazol-5-yl-2,3-dihydro-1H-quinazolin-4-ones as IMPDH inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 23, 2005, Pages 5335-5339

  Birch, Helen L ^a   Buckley, George M ^a   Davies, Natasha ^a   Dyke, Hazel J ^a,b   Frost, Elizabeth J ^a   Gilbert, Philip J ^a   Hannah, Duncan R ^a   Haughan, Alan F ^a   Madigan, Michael J ^a   Morgan, Trevor ^a   Pitt, William R ^a   Ratcliffe, Andrew J ^a   Ray, Nicholas C ^a,b   Richard, Marianna D ^a   Sharpe, Andrew ^a   Taylor, Alicia J ^a   Whitworth, Justine M ^a   Williams, Sophie C ^a  

^a UCB PHARMA   (Belgium)

^b Argenta Discovery Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE II; INOSINATE DEHYDROGENASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; INHIBITION KINETICS;

ENZYME INHIBITORS; HUMANS; IMP DEHYDROGENASE; MOLECULAR CONFORMATION; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 26844435605     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.06.108     Document Type: Article

References (17)

1. A.G. Zimmerman, J.J. Gu, J. Laliberte, and B.S. Mitchell Prog. Nucleic Acid Res. Mol. Biol. 61 1998 181
2. R.C. Jackson, and G. Weber Nature 256 1975 331
3. M.D. Sintchak, and E. Nimmesgern Immunopharmacology 47 2000 163
4. L. Hedstrom Curr. Med. Chem. 6 1999 545
5. F.R. Collart, and E. Huberman J. Biol. Chem. 263 1988 15769
6. H.N. Jayaram, M. Grusch, D.A. Cooney, and G. Krupitza Curr. Med. Chem. 6 1999 561
7. S.F. Carr, E. Papp, J.C. Wu, and Y. Natsumeda J. Biol. Chem. 268 1993 27286
8. W.K. Anderson, T.L. Boehm, G.M. Makara, and R.T. Swann J. Med. Chem. 39 1996 46
9. The IMPDH II enzymatic inhibition protocol is outlined in Ref. 12 (Ref. 15).
10. T.M. Sievers, S.J. Rossi, R.M. Ghobrial, E. Arriola, P. Nishimura, M. Kawano, and C.D. Holt Pharmacotherapy 17 1997 1178
11. L.A. Sorbera, J.S. Silvestre, J. Castaner, and L. Martin Drugs Future 25 2000 809
12. G.M. Buckley, N. Davies, H.J. Dyke, P.J. Gilbert, D.R. Hannah, A.F. Haughan, C.A. Hunt, W.R. Pitt, R.H. Profit, N.C. Ray, M.D. Richard, A. Sharpe, A.J. Taylor, J.M. Whitworth, and S.C. Williams Bioorg. Med. Chem. Lett. 15 2005 751
13. A.K.D. Bhavani, and P.S.N. Reddy Org. Prep. Proc. Int. 24 1992 1
14. S.D. Larsen, M.A. Connell, M.M. Cudahy, B.R. Evans, P.D. May, M.D. Meglasson, T.J. O'Sullivan, H.J. Schostarez, J.C. Sih, F.C. Stevens, S.P. Tanis, C.M. Tegley, J.A. Tucker, V.A. Vaillancourt, T.J. Vidmar, W. Watt, and J.H.J. Yu Med. Chem. 44 2001 1217
15. The PBMC proliferation protocol is outlined in Ref. 12 (Ref. 14).
16. G. Jones, P. Willett, and R.C. Glen J. Mol. Biol. 245 1995 43
17. To investigate human liver microsomal clearance, disappearance of compound was measured over 30 minutes. IMPDH inhibitors (2.5 μM) and microsomal protein (final concentration 1 μg/μL) were pre-incubated at 37°C for 10 min. Reactions were started by the addition of NADPH and subsequent time points were stopped by the addition of acetonitrile containing internal standard (ketoconazole). Samples were centrifuged 10000RPM for 10 min before LCMS analysis.